Journal rankings · indicator year 2024
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2024
Oncology journal rankings 2024
243 ranked journals · Subfield in Medicine
Oncology has 243 ranked journals in 2024. The median journal has an OJR of 0.73, below the world average of 1.00, down 0.02 on 2023; Q1 starts at OJR 1.15. The top three are CA A Cancer Journal for Clinicians, Nature Medicine, and Journal of Hematology & Oncology.
Ranks and citation indicators: 2024. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2021–2023, the window the 2024 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery980
- Pulmonary and Respiratory Medicine364
- Public Health, Environmental and Occupational Health316
- Cardiology and Cardiovascular Medicine289
- Infectious Diseases263
- Oncology243
- Epidemiology187
- Neurology175
- Radiology, Nuclear Medicine and Imaging161
- Physiology159
- Endocrinology, Diabetes and Metabolism157
- Psychiatry and Mental health144
Show all 42 subfields
- Orthopedics and Sports Medicine125
- Ophthalmology100
- Pediatrics, Perinatology and Child Health100
- Dermatology92
- Obstetrics and Gynecology85
- Hematology83
- Rheumatology67
- Nephrology65
- Complementary and alternative medicine59
- Reproductive Medicine52
- Pharmacology49
- Emergency Medicine42
- Geriatrics and Gerontology37
- Rehabilitation34
- Otorhinolaryngology33
- Hepatology30
- Pathology and Forensic Medicine29
- Immunology and Allergy26
- Critical Care and Intensive Care Medicine23
- Genetics19
- Anesthesiology and Pain Medicine14
- Urology12
- Health Informatics9
- Gastroenterology7
- Internal Medicine6
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Microbiology0
243 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2023. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2021–2023, the window the 2024 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2021–2023 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2015 to 2024. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 171.61Q1 | 276.75 417.78 down from 2023 | 83 | 100% | $4,330 | ||
2Nature MedicineNature Portfolio · United States | 11.10Q1 | 32.79 8.24 down from 2023 | 1,239 | 55% | $12,690 | ||
3Journal of Hematology & OncologyOABioMed Central · United Kingdom | 8.20Q1 | 30.21 5.83 up from 2023 | 467 | 100% | $4,990 | ||
4Nature Reviews Clinical OncologyNature Portfolio · United Kingdom | 7.54Q1 | 32.27 0.65 down from 2023 | 367 | 13% | — | ||
5Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 7.33Q1 | 20.22 0.05 down from 2023 | 1,474 | 47% | — | ||
6Cancer CellCell Press · Netherlands | 7.21Q1 | 27.49 5.82 up from 2023 | 544 | 99% | $10,400 | ||
7The Lancet OncologyElsevier BV · United Kingdom | 6.99Q1 | 17.76 3.32 down from 2023 | 907 | 30% | $7,280 | ||
8Cancer DiscoveryAmerican Association for Cancer Research · United States | 6.85Q1 | 23.50 1.10 down from 2023 | 560 | 32% | — | ||
9Nature CancerNature Portfolio · United States | 5.02Q1 | 18.86 2.89 up from 2023 | 440 | 47% | $12,690 | ||
10Journal of the National Comprehensive Cancer NetworkNational Comprehensive Cancer | 4.78Q1 | 14.18 0.64 up from 2023 | 572 | 24% | — | ||
11Annals of OncologyElsevier BV · Netherlands | 3.96Q1 | 9.46 7.59 down from 2023 | 1,138 | 99% | $5,080 | ||
12Seminars in Cancer BiologyElsevier BV · United States | 3.93Q1 | 16.85 5.28 up from 2023 | 477 | 46% | $6,060 | ||
13JAMA OncologyAmerican Medical Association · United States | 3.14Q1 | 8.69 0.92 down from 2023 | 1,097 | 49% | — | ||
14American Society of Clinical Oncology Educational BookAmerican Society of Clinical Oncology · United States | 3.10Q1 | 9.49 2.11 up from 2023 | 209 | 63% | — | ||
15Cell Reports MedicineOAElsevier BV · United States | 2.97Q1 | 9.04 0.83 down from 2023 | 850 | 100% | $5,620 | ||
16Clinical Cancer ResearchAmerican Association for Cancer Research · United States | 2.94Q1 | 8.82 0.79 down from 2023 | 1,740 | 46% | — | ||
17European Journal of EpidemiologySpringer Science+Business Media · Italy | 2.92Q1 | 6.43 1.63 down from 2023 | 332 | 81% | $3,690 | ||
18Journal for ImmunoTherapy of CancerOABMJ · United Kingdom | 2.91Q1 | 10.55 0.26 down from 2023 | 1,494 | 100% | $2,490 | ||
19Cancer Treatment ReviewsElsevier BV · United Kingdom | 2.67Q1 | 11.56 1.13 up from 2023 | 295 | 59% | $4,910 | ||
20npj Precision OncologyOANature Portfolio · United Kingdom | 2.46Q1 | 8.87 0.99 up from 2023 | 326 | 100% | $4,090 | ||
21JNCI Journal of the National Cancer InstituteOxford University Press · United States | 2.45Q1 | 6.69 1.77 down from 2023 | 533 | 89% | $5,436 | ||
22ImmunoTargets and TherapyOADove Medical Press · New Zealand | 2.41Q1 | 5.00 2.68 down from 2023 | 51 | 100% | $2,320 | ||
23Journal of the National Cancer CenterOAElsevier BV · China | 2.31Q1 | 8.90 1.12 down from 2023 | 103 | 100% | $2,160 | ||
24British Journal of CancerSpringer Nature · United Kingdom | 2.13Q1 | 7.08 0.29 up from 2023 | 1,238 | 99% | $5,190 | ||
25npj Breast CancerOANature Portfolio · United States | 2.06Q1 | 8.19 0.86 up from 2023 | 374 | 100% | $3,790 | ||
26Current Oncology ReportsSpringer Science+Business Media · United States | 2.05Q1 | 5.74 0.04 up from 2023 | 447 | 40% | $5,090 | ||
27ESMO OpenOAElsevier BV · Netherlands | 2.05Q1 | 6.79 0.44 down from 2023 | 755 | 100% | $3,910 | ||
28MedElsevier BV · United States | 2.02Q1 | 6.30 0.26 down from 2023 | 310 | 97% | $9,350 | ||
29BMJ OncologyOABMJ | 1.99Q1 | 4.31no 2023 value | 36 | 100% | — | — | |
30International Journal of CancerWiley · United States | 1.91Q1 | 4.94 1.35 down from 2023 | 1,170 | 77% | $5,030 | ||
31Cancer Immunology ResearchAmerican Association for Cancer Research · United States | 1.90Q1 | 7.12 0.12 up from 2023 | 379 | 31% | — | ||
32Clinical Pharmacology & TherapeuticsWiley · United States | 1.89Q1 | 5.42 0.19 down from 2023 | 846 | 72% | $4,410 | ||
33European Journal of CancerElsevier BV · United Kingdom | 1.85Q1 | 6.36 0.47 down from 2023 | 1,376 | 43% | $4,270 | ||
34Breast Cancer ResearchOABioMed Central · United Kingdom | 1.82Q1 | 6.17 0.81 down from 2023 | 352 | 100% | $4,190 | ||
35Current Treatment Options in OncologySpringer Science+Business Media · United States | 1.81Q1 | 5.49 0.93 up from 2023 | 339 | 47% | $4,890 | ||
36CancerWiley · United States | 1.73Q1 | 4.32 0.78 down from 2023 | 1,524 | 77% | $4,790 | ||
37OncoImmunologyOALandes Bioscience · United States | 1.60Q1 | 6.00 0.48 down from 2023 | 527 | 100% | $2,913 | ||
38Expert Opinion on Investigational DrugsTaylor & Francis · United Kingdom | 1.54Q1 | 4.30 1.06 down from 2023 | 287 | 26% | — | ||
39The OncologistOAAlphaMed Press · United Kingdom | 1.52Q1 | 4.43 0.41 down from 2023 | 942 | 100% | $3,852 | ||
40Molecular Cancer TherapeuticsAmerican Association for Cancer Research · United States | 1.51Q1 | 4.81 0.39 down from 2023 | 516 | 32% | — | ||
41Trends in cancerElsevier BV · United States | 1.49Q1 | 10.73 1.80 up from 2023 | 364 | 58% | $7,030 | ||
42Chinese Journal of Cancer ResearchOAAME Publishing Company · China | 1.48Q1 | 4.61 0.31 up from 2023 | 161 | 100% | — | ||
43CancersOAMultidisciplinary Digital Publishing Institute · Switzerland | 1.46Q1 | 4.90 0.15 down from 2023 | 18,499 | 100% | $3,499 | ||
44Cancer Immunology ImmunotherapyOASpringer Science+Business Media · Germany | 1.43Q1 | 5.43 0.24 up from 2023 | 727 | 100% | $4,590 | ||
45Cancer Biology and MedicineOAChinese Anti-Cancer Association · China | 1.43Q1 | 5.91 0.68 up from 2023 | 290 | 100% | $1,500 | ||
46JNCI Cancer SpectrumOAOxford University Press · United Kingdom | 1.38Q1 | 4.47 0.59 up from 2023 | 268 | 100% | $2,050 | ||
47Critical Reviews in Oncology/HematologyElsevier BV · Netherlands | 1.37Q1 | 6.08 0.37 up from 2023 | 625 | 44% | $4,190 | ||
48BMJ Open GastroenterologyOABMJ · United Kingdom | 1.34Q1 | 3.45 0.81 down from 2023 | 233 | 100% | $2,085 | ||
49JMIR CancerOAJMIR Publications · Canada | 1.33Q1 | 3.31 0.80 down from 2023 | 198 | 100% | $1,873 | ||
50Therapeutic Advances in Medical OncologyOASAGE Publishing · United Kingdom | 1.33Q1 | 4.67 0.09 down from 2023 | 506 | 100% | $2,800 |
Subfields of Medicine, with Oncology highlighted.
- Surgery980
- Pulmonary and Respiratory Medicine364
- Public Health, Environmental and Occupational Health316
- Cardiology and Cardiovascular Medicine289
- Infectious Diseases263
- Oncology243
- Epidemiology187
- Neurology175
- Radiology, Nuclear Medicine and Imaging161
- Physiology159
- Endocrinology, Diabetes and Metabolism157
- Psychiatry and Mental health144
- Orthopedics and Sports Medicine125
- Ophthalmology100
- Pediatrics, Perinatology and Child Health100
- Dermatology92
- Obstetrics and Gynecology85
- Hematology83
- Rheumatology67
- Nephrology65
- Complementary and alternative medicine59
- Reproductive Medicine52
- Pharmacology49
- Emergency Medicine42
- Geriatrics and Gerontology37
- Rehabilitation34
- Otorhinolaryngology33
- Hepatology30
- Pathology and Forensic Medicine29
- Immunology and Allergy26
- Critical Care and Intensive Care Medicine23
- Genetics19
- Anesthesiology and Pain Medicine14
- Urology12
- Health Informatics9
- Gastroenterology7
- Internal Medicine6
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Microbiology0
Journals
Citations made in 2024. Corpus-wide, 87.1% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
68 additional Oncology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2021–2023, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2024. Publication window: 2021–2023. How these summaries are calculated
- Ranked journals
- 243
- Window papers (baseline)
- 163,907 +17.4% from indicator year 2021
- Median OJR
- 0.73 -11.8% from indicator year 2021
- Rising journals (2025)
- 20
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2021–2023 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 82 | 88 | 96 | 103 | 109 | 120 | 120 | 126 | 127 | 134 | 141 | 150 | 153 | 170 | 179 | 188 | 198 | 213 | 224 | 234 | 238 | 239 | 245 | 245 | 243 | 242 | |
| Window papers (baseline) | 37,821 | 41,430 | 44,340 | 47,392 | 49,058 | 53,111 | 57,002 | 62,106 | 66,087 | 71,283 | 77,009 | 82,075 | 86,189 | 88,804 | 93,912 | 98,660 | 102,921 | 105,891 | 109,984 | 115,044 | 121,890 | 139,666 | 156,942 | 167,602 | 163,907 | 160,807 | |
| Median OJR | 0.55 | 0.62 | 0.70 | 0.799 | 0.805 | 0.831 | 0.85 | 0.90 | 0.94 | 0.93 | 1.010 | 0.95 | 1.006 | 0.974 | 0.972 | 0.967 | 0.832 | 0.84 | 0.82 | 0.79 | 0.829 | 0.830 | 0.77 | 0.750 | 0.73 | 0.748 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.